News | July 02, 2024
Abbott and YRGCARE inaugurate new outreach centers in India
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
Austin assumes role from Glenn F. Tilton, who will continue to serve as an independent director
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
Further strengthens BaseLaunch's global pharma industry partnerships
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
The company has posted net profit of Rs. 1,201.22 crores for the Financial Year ended March 31, 2024
Open a printable version of this pageEmail the URL of this page to a friend
Subscribe To Our Newsletter & Stay Updated
